NOT KNOWN DETAILS ABOUT JOURNAL OF RHEUMATOLOGY AND ARTHRITIS

Golimumab is usually a human monoclonal antibody administered as soon as per month by subcutaneous injection. While it's got a similar safety and efficacy profile to other TNFi, golimumab is a lot less productive than other TNFi in people who have unsuccessful numerous biological treatments.Work on a cure plan together with your healthcare company